VIVO News and Press, Meridian Bioscience Inc. From 04/07/22

Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter PR Newswire CINCINNATI , April 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and li...

Meridian Bioscience Launches Lyo-Ready™ qPCR Inhibitor Tolerant Blood-Specific Master Mixes for DNA & RNA Direct Detection Meridian Bioscience Launches Lyo-Ready™ qPCR Inhibitor Tolerant Blood-Specific Master Mixes for DNA & RNA Direct Detection PR News...

Sometimes the best healthcare stocks are hiding in plain sight. They may not be the largest companies or make the most news, but instead consistently produce strong numbers. The best part about stocks such as these is they're bargains because they're not necessarily household names. Two...

At first glance, shares of Meridian Bioscience look quite affordable, especially considering recent growth. But investors need to pay attention to the likely temporary improvement caused by the COVID-19 pandemic. Adjusting for this, the company looks much more expensive than it do...

Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer PR Newswire CINCINNATI, Ohio , Feb. 21, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, a...

Magellan Diagnostics Resumes Distribution of LeadCare® II Test Kits PR Newswire CINCINNATI , Feb. 16, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials...

We identified 18 stocks in S&P 500 with strong momentum based on our criteria. Ten of the stocks we identified made new all-time highs. Five of these stocks are 40% or more above their 200-day moving average. For further details see: S&P 500 Stocks With Strong Mo...

Meridian Bioscience, Inc. (VIVO) Q1 2022 Earnings Conference Call February 4, 2022 10:00 A.M. ET Company Participants Charlie Wood - Vice President, Investor Relations Jack Kenny - Chief Executive Officer Julie Smith - Senior Vice President Controller & Principal Accounting Officer Confer...

Meridian Bioscience (VIVO +5.4%) rose following its Q1 results and a raised fiscal 2022 guidance. The company said net revenues in Q1 fiscal were $88.3M, only 5% below the record $92.9M in Q1 fiscal 2021. Diagnostics segment net revenues increased 10% Y/Y to $33.2M. The company said the ...

Gainers: IRadimed IRMD +8%. Meridian Bioscience VIVO +8%. Biofrontera (NASDAQ:BFRI) +6%. Inspira Technologies Oxy (NASDAQ:IINN) +6%. Taysha Gene Therapies (NASDAQ:TSHA) +5%. Losers: Lannett Company (NYSE:LCI) -24%. Vanda Pharmaceuticals (NASDAQ:VNDA) -22%. E...